{"id":6892,"date":"2013-05-28T06:34:51","date_gmt":"2013-05-28T10:34:51","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=6892"},"modified":"2013-05-28T06:35:09","modified_gmt":"2013-05-28T10:35:09","slug":"valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892","title":{"rendered":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 05\/28\/2013 (wallstreetpr) &#8211;\u00a0In Friday\u2019s trading session, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rose by 13.12%. It opened at $74.30 per share, touched an intraday high of $87.50 and dropped down to close at $73.25 per share. More than 10.38 million shares were traded in Friday\u2019s trading session. This number stood above the average volume of 1.55 million that was measured over a 30-day period.<\/p>\n<p style=\"text-align: justify;\">On Friday, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and the global eye health company, Bausch + Lomb Holdings Incorporated, announced that they have now entered into a definitive agreement. Under this agreement, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) will acquire Bausch + Lomb for an amount of $8.7 billion in cash. Under the agreement terms, the Board\u2019s of both these companies, unanimously approved that Valeant will pay an aggregate consideration of cash of $8.7 billion.<\/p>\n<p style=\"text-align: justify;\">Of this amount, approximately $4.5 billion will be going to an investor group that is led by Warburg Pincus and around $4.2 billion will be utilized to repay the outstanding debt that Bausch + Lomb currently has. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) expects to achieve at minimum of $800 million in annual cost savings by 2014 end. Bausch + Lomb expects to have revenues of around $3.3 billion and a 2013, adjusted EBITDA of around $720 million. This transaction is expected to be accretive immediately to Valeant Pharmaceuticals Intl Inc (NYSE:VRX) cash earnings per share.<\/p>\n<p style=\"text-align: justify;\">Valeant was formerly Biovail Corporation. It is a specialty multinational,\u00a0\u00a0 pharma company that is involved in developing, manufacturing and marketing a variety of pharmaceutical products.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 05\/28\/2013 (wallstreetpr) &#8211;\u00a0In Friday\u2019s trading session, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rose by 13.12%. It opened at $74.30 per share, touched an intraday [&hellip;]<\/p>\n","protected":false},"author":13,"featured_media":6893,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2046,2045],"stock_ticker":[],"class_list":["post-6892","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysevrx","tag-valeant-pharmaceuticals-intl-inc-nysevrx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 05\/28\/2013 (wallstreetpr) &#8211;\u00a0In Friday\u2019s trading session, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rose by 13.12%. It opened at $74.30 per share, touched an intraday [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-05-28T10:34:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2013-05-28T10:35:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/slide-1-1024-13.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lisa Ray\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lisa Ray\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892\"},\"author\":{\"name\":\"Lisa Ray\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c\"},\"headline\":\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb\",\"datePublished\":\"2013-05-28T10:34:51+00:00\",\"dateModified\":\"2013-05-28T10:35:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892\"},\"wordCount\":256,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/slide-1-1024-13.jpg\",\"keywords\":[\"NYSE:VRX\",\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892\",\"name\":\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/slide-1-1024-13.jpg\",\"datePublished\":\"2013-05-28T10:34:51+00:00\",\"dateModified\":\"2013-05-28T10:35:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/slide-1-1024-13.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/slide-1-1024-13.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c\",\"name\":\"Lisa Ray\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png\",\"caption\":\"Lisa Ray\"},\"description\":\"Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/linsay-thomas\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892","og_locale":"en_US","og_type":"article","og_title":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb  - Wall Street PR","og_description":"Boston, MA 05\/28\/2013 (wallstreetpr) &#8211;\u00a0In Friday\u2019s trading session, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rose by 13.12%. It opened at $74.30 per share, touched an intraday [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-05-28T10:34:51+00:00","article_modified_time":"2013-05-28T10:35:09+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/slide-1-1024-13.jpg","type":"image\/jpeg"}],"author":"Lisa Ray","twitter_misc":{"Written by":"Lisa Ray","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892"},"author":{"name":"Lisa Ray","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c"},"headline":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb","datePublished":"2013-05-28T10:34:51+00:00","dateModified":"2013-05-28T10:35:09+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892"},"wordCount":256,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/slide-1-1024-13.jpg","keywords":["NYSE:VRX","Valeant Pharmaceuticals Intl Inc (NYSE:VRX)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892","url":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892","name":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/slide-1-1024-13.jpg","datePublished":"2013-05-28T10:34:51+00:00","dateModified":"2013-05-28T10:35:09+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/slide-1-1024-13.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/slide-1-1024-13.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-acquires-bausch-lomb-6892#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquires Bausch + Lomb"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c","name":"Lisa Ray","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png","caption":"Lisa Ray"},"description":"Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/linsay-thomas"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/6892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=6892"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/6892\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/6893"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=6892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=6892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=6892"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=6892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}